• TSPAN18 and STIM1 in Prostate Cancer Bone Metastasis

  2026-10-22

  Zhou and colleagues describe a mechanistic link between TSPAN18, STIM1 stability, store-operated calcium entry, and prostate cancer bone metastasis. This editorial distinguishes molecular interaction evidence from functional and clinical association data, examines the study’s layered design and comparators, and defines the limits of translating a preclinical TSPAN18–STIM1 model into therapeutic claims. Toremifene is discussed only as a separate selective estrogen-receptor modulator context.

• Interpreting Milademetan Cell-Fate Readouts

  2026-10-21

  Milademetan (DS-3032) is described as producing G1 cell-cycle arrest, senescence, and apoptosis, but these are distinct biological readouts rather than interchangeable evidence of one mechanism. A careful interpretation separates documented product claims from the molecular pathway, model context, and measurements needed to establish causality.

• SIRT1, Bone Aging, and Vascular Coupling

  2026-10-21

  Liu et al. examined how declining SIRT1 activity may connect skeletal aging with loss of type H vasculature and impaired osteogenesis. Their mouse and cell-based evidence implicates β-catenin and reciprocal paracrine signaling, while EX 527 (SEN0014196) served as a pharmacological SIRT1-inhibition comparator rather than evidence of a therapeutic effect.

• What Does p53 Lys382 Acetylation Indicate?

  2026-10-20

  A p53 Lys382 acetylation signal is best understood as a molecular-state measurement, not a direct readout of p53 activity or cell fate. This article explains how a modification-specific antibody can connect an acetylated p53 epitope to an assay signal, and where that interpretation must stop.

• EX 527: A Bounded SIRT1 Mechanism Overview

  2026-10-19

  EX 527, also known as SEN0014196, is described by APExBIO as a racemic small-molecule inhibitor of SIRT1 catalytic activity. The product information supports an assay-specific interpretation involving SIRT1 deacetylase activity and p53 acetylation, but it does not provide an identity-matched primary study establishing broader disease mechanisms, therapeutic effects, or comprehensive selectivity.

• Hematoxylin and Eosin Staining Kit: Scope and Evidence

  2026-10-18

  APExBIO’s K1142 Hematoxylin and Eosin Staining Kit is described as a research-use solution set for visualizing cellular and tissue morphology. Its documented principle is differential staining: hematoxylin-based complexes produce blue to bluish-purple nuclear contrast, while eosin produces pink to reddish staining of cytoplasmic and extracellular components. The product information supports interpretation as a broad morphology readout, but provides no identity-matched study, performance statistics, comparator data, or independent validation. Accordingly, the kit’s documented scope should not be extended to diagnostic conclusions, molecular-mechanism claims, or quantitative performance claims.

• KU-60019: Evidence-Limited Product Overview

  2026-10-17

  The available APExBIO listing identifies KU-60019 by catalog number BA3711, but provides no product description or identity-matched research evidence in the supplied material. Consequently, its mechanism, measurement role, performance, and biological applicability cannot be established from the available record.

• Red Blood Cell Lysis Buffer: Evidence and Scope

  2026-10-16

  APExBIO’s K1169 Red Blood Cell Lysis Buffer is described as an ammonium chloride–containing solution intended to disrupt erythrocytes in mammalian blood or tissue samples while preserving nucleated cells. The available evidence establishes product identity, stated scope, and a conceptual selective-lysis principle, but it does not provide an identity-matched research study, quantitative performance data, independent mechanistic validation, or direct comparisons with alternative buffers. Its relevance to flow cytometry, nucleic acid extraction, and protein extraction is therefore best understood as a documented sample-preparation use case rather than a demonstrated outcome.

• EX 527 (SEN0014196): Evidence and Scope

  2026-10-16

  APExBIO describes EX 527, also designated SEN0014196, as a racemic small-molecule inhibitor of SIRT1 catalytic activity. The product page reports an assay-specific SIRT1 IC50 of 98 nM, selectivity relative to SIRT2 and SIRT3, and findings involving p53 acetylation in cellular and rat contexts. Because no identity-matched research paper is available here, these claims are best interpreted as supplier-reported evidence rather than an independently verified literature base.

• Mitomycin C: DNA Damage and Topoisomerase Evidence

  2026-10-15

  Mitomycin C is best understood as a bioreduction-dependent DNA-alkylating antitumor antibiotic. A public-data mining study added evidence consistent with topoisomerase IIβ-associated cleavage-complex formation, but its computational similarities and cell-based measurements do not establish a single primary molecular target or clinical activity.

• CGK733: Evidence and Scope of the Product Listing

  2026-10-15

  The APExBIO listing identifies CGK733 as product A8624, but the available product information provides no molecular identity, mechanism, assay context, or research findings. Accordingly, CGK733 can be discussed here only as a commercially named material whose biological interpretation remains undocumented in the cited source.

• CGK733: Evidence Boundaries of a Catalog Entry

  2026-10-14

  The available APExBIO catalog page identifies CGK733 as product A8624 but provides no description, mechanism, assay context, or identity-matched research evidence. Accordingly, this overview separates catalog provenance from claims about molecular targets, biological effects, or measurement interpretation.

• Ibuprofen Research Claims: Evidence and Limits

  2026-10-14

  The supplied materials describe Ibuprofen, or 2-[4-(2-methylpropyl)phenyl]propanoic acid, as a non-steroidal anti-inflammatory drug and summarize possible anticancer findings in model systems. However, the cited peer-reviewed study concerns mubritinib–albumin recognition rather than ibuprofen. Its biochemical observations therefore provide useful context for drug–protein research but do not validate ibuprofen’s reported anticancer effects or clinical pharmacology.

• Thiothixene: Evidence, Mechanisms and Limits

  2026-10-13

  Thiothixene is a typical antipsychotic agent with established dopamine-receptor pharmacology, while proposed roles in macrophage efferocytosis remain less independently documented. A small randomized crossover pharmacokinetic study found no significant effect of short-term paroxetine exposure on thiothixene disposition, but its healthy-volunteer sample and brief exposure limit interpretation.

• Lanabecestat and the Limits of Partial BACE1 Inhibition

  2026-10-13

  Lanabecestat (AZD3293) is a blood-brain barrier-penetrant BACE1 inhibitor described for Alzheimer’s disease research. In a rat neuronal-culture study, partial amyloid-beta reduction was not associated with impaired synaptic transmission, whereas stronger inhibition was. The findings support a biologically conditional view of BACE1 inhibition, but they do not establish clinical efficacy, safety, or a universal therapeutic exposure range.

8695 records 2/580 page Previous Next 12345 下5页 Last page